GCTKHIGH SIGNALOPERATIONAL10-K

GCTK has withdrawn its CE Mark approval for Glucotrack and abandoned commercialization while undergoing a dramatic share consolidation that reduced outstanding shares from 25.6M to 1.9M.

The withdrawal of European regulatory approval and cessation of commercialization efforts represents a major strategic pivot that eliminates near-term revenue prospects for the company's primary product. The massive share consolidation suggests potential financial distress or preparation for recapitalization, fundamentally altering the equity structure for existing shareholders.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position shows mixed signals with a substantial reduction in total liabilities from $18.9M to $5.0M and improved cash position growing to $7.4M from $5.6M. However, operating losses widened to $16.1M while operating cash burn increased to $15.2M, indicating continued cash consumption despite the liability reduction. The combination of higher cash levels with increased burn rates suggests recent fundraising activity that may provide limited runway given current spending levels.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
-73.5%
$18.9M→$5.0M

Liabilities reduced 73.5% — deleveraging improves balance sheet strength and financial flexibility.

SG&A Expense
P&L
-66.5%
$415K→$139K

SG&A reduced 66.5% — improved cost efficiency or headcount reduction improving operating margins.

Inventory
Balance Sheet
+53.8%
$185K→$284K

Inventory surged 53.8% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+32.9%
$5.8M→$7.7M

Current assets grew 32.9% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+32.1%
$5.9M→$7.8M

Asset base grew 32.1% — expansion through organic growth, acquisitions, or capital deployment.

Cash & Equivalents
Balance Sheet
+31.4%
$5.6M→$7.4M

Cash position surged 31.4% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
-22%
-$12.5M→-$15.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Net Income
P&L
+14.2%
-$22.6M→-$19.4M

Net income grew 14.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
-10.6%
-$14.5M→-$16.1M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
As of March 30, 2026, there were 1,944,279 shares of Common Stock, par value $ 0.001 per share, of the registrant issued and outstanding.
Directors, Executive Officers and Corporate Governance 45 Item 11 Executive Compensation 48 Item 12.
We are a medical device company focused on the development of an implantable continuous blood glucose monitor ( CBGM ) for persons with Type 1 diabetes and Type 2 diabetes using insulin or at risk for hypoglycemia (the Glucotrack CBGM ).
As such, the Company withdrew the CE Mark for Glucotrack and are no longer pursuing commercialization of this product or development of any further iterations.
The Company is currently developing the Glucotrack CBGM for use by Type 1 diabetes patients as well as Type 2 diabetes using insulin or at risk for hypoglycemia..
The Company believes this approach may enable integrated chronic disease management with one system that provides dual benefits of pain relief and glucose monitoring.
Initial results were presented in poster form at the 2025 Advanced Technologies Treatments for Diabetes annual meeting and final results were presented in poster form at the 2025 American Diabetes Association annual conference.
The Company initiated a long-term, multicenter feasibility study in Australia to evaluate the CBGM product performance and safety.
The first phase of the clinical study provided early product learnings about how the complexity of certain health conditions may impact study eligibility as well as identified certain product improvements.
Following a reassessment of the study in light of planned product updates and anticipated protocol modifications, the Company determined that continuation of the study in its current form was no longer practical and elected to close the study.
REMOVED
As of March 31, 2025, there were 25,585,853 shares of Common Stock, par value $ 0.001 per share, of the registrant issued and outstanding.
Directors, Executive Officers and Corporate Governance 47 Item 11 Executive Compensation 50 Item 12.
We are a medical device company focused on the development of an implantable continuous blood glucose monitor ( CBGM ) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the Glucotrack CBGM ).
As such, we have since withdrawn our CE Mark for Glucotrack and are no longer pursuing commercialization of this product or development of any further iterations.
The Company is currently developing the Glucotrack CBGM for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients.
A regulatory submission has recently been made for a first in human study of the planned commercial version of the Glucotrack CBGM system: fully implantable sensor and electronics with no on-body wearable.
This will be a long-term study intended to demonstrate device performance and safety over a period of at least one year.
Most of the preparatory clinical activities are complete and the study is expected to initiate late in the second quarter of 2025, pending regulatory approval.
In parallel, the Company is also preparing for pre-submission discussions with the U.S.
As part of this effort, the Company has recently obtained ISO13485 certification, an internationally agreed-upon standard of quality system requirements for the design, production, distribution, and sale of medical devices.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →